DPBIO

DPBIO (operating under dp-bio.com, legally DPBIO Inc.) is a pioneering life sciences infrastructure, hardware-plus-consumables developer, and frontier biotechnology platform specializing in ultra-high-throughput droplet microfluidic technologies engineered for the AI plus BIO era. Incubated out of the Hong Kong University of Science and Technology (HKUST) and founded in 2018 by leading microfluidic researcher Dr. Xu Xiaonan, the corporation addresses severe capacity constraints in legacy single-cell biology—where standard flow cytometry (FACS) and bulk screening methods fail to capture functional cellular dynamics at scale, or incur prohibitive reagent costs. DPBIO closed these operational gaps by pioneering a comprehensive, vertically integrated ecosystem encompassing microfluidic chips, desktop scientific instrumentation, automated operating software, and proprietary biochemical reagents. The company's flagship commercial instrument, the CytoSpark High-throughput Screening System, utilizes microfluidic oil-and-water droplet technology to encapsulate, isolate, and assay single cells at a speed of up to 1.5 KHz, empowering researchers to perform functional screens on over 10 million single B-cells or microbial strains in a compressed 1-to-2 day cycle. Alongside its cornerstone system, DPBIO markets the OMNIdrop system—a high-precision, four-channel fluidic generation tool optimized for flexible cell encapsulation and rapid target reagent mixing. By generating massive, highly standardized, and traceable functional datasets across single-cell multi-omics, enzyme evolution, and therapeutic discovery workflows, the company serves as the critical wet-lab data engine required to fuel complex generative AI biological models. In a massive commercial inflection point, the firm closed an over RMB 120 million ($16.5M+ USD) Series B+ financing round to rapidly build out local validation labs, regional service hubs, and dedicated sales forces across major global life science clusters. Headquartered globally with integrated cross-border operational systems bridging San Francisco and San Diego, California, alongside strategic R&D and scaling entities in Boston, Massachusetts, Heidelberg, Germany, and the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), DPBIO stands as a definitive technological standard for automated cellular screening—replacing slow, discrete laboratory assays with continuous, high-fidelity microfluidic discovery infrastructure.